Immunosuppressive dead cell as lung-targeting vehicle and cytokine absorption material for cytokine storm attenuation of pneumonia

[1]  T. Guo,et al.  Cytokine nanosponges suppressing overactive macrophages and dampening systematic cytokine storm for the treatment of hemophagocytic lymphohistiocytosis , 2022, Bioactive materials.

[2]  Sha Li,et al.  Cryo-Shocked Cancer Cells as an Oncolytic Adenovirus Reservoir for Glioblastoma Immunotherapy. , 2022, ACS applied materials & interfaces.

[3]  Ronnie H. Fang,et al.  Targeting drugs to tumours using cell membrane-coated nanoparticles , 2022, Nature reviews. Clinical oncology.

[4]  Ronnie H. Fang,et al.  Nanoparticle-modified microrobots for in vivo antibiotic delivery to treat acute bacterial pneumonia , 2022, Nature Materials.

[5]  Ronnie H. Fang,et al.  Biomimetic Neutrophil Nanotoxoids Elicit Potent Immunity against Acinetobacter baumannii in Multiple Models of Infection. , 2022, Nano letters.

[6]  Ruibing Wang,et al.  Supramolecular erythrocytes-hitchhiking drug delivery system for specific therapy of acute pneumonia. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Weiyue Zhang,et al.  Stem cell membrane-camouflaged targeted delivery system in tumor , 2022, Materials today. Bio.

[8]  junhao jiang,et al.  Biomimetic macrophage membrane-coated gold-quantum dots with tumor microenvironment stimuli-responsive capability for tumor theranostic , 2022, Materials today. Bio.

[9]  Yaping Li,et al.  Walking Dead Tumor Cells for Targeted Drug Delivery Against Lung Metastasis of Triple‐Negative Breast Cancer , 2022, Advanced materials.

[10]  Qin Fan,et al.  Recent applications of immunomodulatory biomaterials for disease immunotherapy , 2022, Exploration.

[11]  B. Lei,et al.  Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapy , 2022, Materials today. Bio.

[12]  X. Lou,et al.  Erythrocyte membrane-camouflaged nanoparticles as effective and biocompatible platform: Either autologous or allogeneic erythrocyte-derived , 2022, Materials today. Bio.

[13]  Shaoduo Yan,et al.  Neutrophil membrane-mimicking nanodecoys with intrinsic anti-inflammatory properties alleviate sepsis-induced acute liver injury and lethality in a mouse endotoxemia model , 2022, Materials today. Bio.

[14]  Yuan Zhong,et al.  Cell membrane camouflaged biomimetic nanoparticles: Focusing on tumor theranostics , 2022, Materials today. Bio.

[15]  Yan Ding,et al.  RBC-hitchhiking chitosan nanoparticles loading methylprednisolone for lung-targeting delivery , 2021, Journal of Controlled Release.

[16]  Yuchen Qi,et al.  Lung-Targeting Lysostaphin Microspheres for Methicillin-Resistant Staphylococcus aureus Pneumonia Treatment and Prevention. , 2021, ACS nano.

[17]  Wei He,et al.  Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome , 2021, Acta Pharmaceutica Sinica B.

[18]  Jinrong Fu,et al.  The signal pathways and treatment of cytokine storm in COVID-19 , 2021, Signal Transduction and Targeted Therapy.

[19]  T. Kanneganti,et al.  The 'cytokine storm': molecular mechanisms and therapeutic prospects. , 2021, Trends in immunology.

[20]  Zhuang Liu,et al.  Immunosuppressive Nanoparticles for Management of Immune-Related Adverse Events in Liver. , 2021, ACS nano.

[21]  T. van der Poll,et al.  Pneumonia , 2021, Nature Reviews Disease Primers.

[22]  Shan Xue,et al.  Clinical characteristics and related risk factors of disease severity in 101 COVID-19 patients hospitalized in Wuhan, China , 2021, Acta pharmacologica Sinica.

[23]  M. Dukhinova,et al.  Macrophage-derived cytokines in pneumonia: Linking cellular immunology and genetics , 2020, Cytokine & Growth Factor Reviews.

[24]  C. June,et al.  Cytokine Storm , 2020, The New England journal of medicine.

[25]  Zhen Gu,et al.  Cryo-shocked cancer cells for targeted drug delivery and vaccination , 2020, Science Advances.

[26]  S. Mitragotri,et al.  Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases , 2020, Nature Biomedical Engineering.

[27]  J. Parr.  Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia. , 2020, JAMA internal medicine.

[28]  T. Asselah,et al.  COVID-19: Discovery, diagnostics and drug development , 2020, Journal of Hepatology.

[29]  Naomi I Maria,et al.  The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm , 2020, Arthritis & rheumatology.

[30]  Xiang Ren,et al.  Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version) , 2020, Military Medical Research.

[31]  Sang-Hyun Kim,et al.  Triamcinolone-Gold Nanoparticles Repolarize Synoviocytes and Macrophages in Inflamed Synovium. , 2020, ACS applied materials & interfaces.

[32]  Christopher J. Lyon,et al.  Nanomedicine therapies modulating Macrophage Dysfunction: a potential strategy to attenuate Cytokine Storms in severe infections , 2020, Theranostics.

[33]  Suwen Zhao,et al.  Structural basis of CXC chemokine receptor 2 activation and signalling , 2020, Nature.

[34]  C. Hunter,et al.  Cytokine Storms: Understanding COVID-19 , 2020, Immunity.

[35]  C. Solinas,et al.  A critical evaluation of glucocorticoids in the management of severe COVID-19 , 2020, Cytokine & Growth Factor Reviews.

[36]  U. Häfeli,et al.  Monosized Polymeric Microspheres Designed for Passive Lung Targeting: Biodistribution and Pharmacokinetics after Intravenous Administration. , 2020, ACS nano.

[37]  N. Zhang,et al.  Selective inhibition of Tumor necrosis factor receptor-1 (TNFR1) for the treatment of autoimmune diseases. , 2020, Cytokine & growth factor reviews.

[38]  Yan Zhao,et al.  A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) , 2020, Military Medical Research.

[39]  Ronnie H. Fang,et al.  Multiantigenic Nanotoxoids for Antivirulence Vaccination against Antibiotic-Resistant Gram-Negative Bacteria. , 2019, Nano letters.

[40]  T. Hirano,et al.  Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. , 2019, Immunity.

[41]  L. Quinton,et al.  Integrative Physiology of Pneumonia. , 2018, Physiological reviews.

[42]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[43]  L. Leibovici,et al.  Corticosteroids for pneumonia. , 2011, The Cochrane database of systematic reviews.

[44]  X. Wang,et al.  Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis , 2016, Osteoporosis International.

[45]  C. Sung,et al.  Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury: An animal study. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[46]  L. Quinton,et al.  Dynamics of lung defense in pneumonia: resistance, resilience, and remodeling. , 2015, Annual review of physiology.

[47]  Samir Mitragotri,et al.  Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. , 2013, ACS nano.

[48]  G. Freund,et al.  IL-1 receptor 2 (IL-1R2) and its role in immune regulation , 2013, Brain, Behavior, and Immunity.

[49]  D. Laskin,et al.  Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[50]  Samson S. Y. Wong,et al.  Delayed Clearance of Viral Load and Marked Cytokine Activation in Severe Cases of Pandemic H1N1 2009 Influenza Virus Infection , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  A. Ahuja,et al.  Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. , 2005, Radiology.